ARMO BioSciences Announces Presentation on Promising Immuno-Oncology Program at 2015 ASCO Annual Meeting

Redwood City, CA, May 13, 2015 — ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced that clinical data from a Phase 1 clinical trial of AM0010, a PEGylated form of recombinant human interleukin-10 (IL-10), will be highlighted at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2015 in Chicago, IL.

A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors (Abstract #3017)

  • Poster Presentation: Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology
  • Session Track: Developmental Therapeutics and Translational Research
  • Date and Time: Saturday, May 30, 2015, 8:00 a.m. – 11:30 a.m. CDT
  • Location: S Hall A

A poster discussion will take place on May 30, 2015 from 3:00 p.m. – 4:15 p.m. CDT in Room S406, poster #343.

Data contained in the published abstract was current as of the submission deadline of February 3, 2015.

About AM0010

Preclinical studies have shown that AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-rHuIL-10), directly activates tumor specific CD8+ killer T lymphocytes. In preclinical models, these activated CD8+ killer T lymphocytes completely eradicate large tumor masses and significantly reduce metastatic disease while establishing a lasting anti-tumor immune surveillance. ARMO plans to develop this unique molecule for known indications and innovative applications including cancer. ARMO has over 53 issued and pending US and foreign patents and applications covering compositions of matter, methods of use, and methods of manufacturing of AM0010.

About ARMO BioSciences, Inc.

ARMO BioSciences is focused on developing immunotherapies for the treatment of cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. ARMO believes that by harnessing the body's own capability to arm itself against dysregulated cells, it may provide safer and more effective drugs for patients suffering from grievous diseases. ARMO’s medicines are designed to normalize the underlying biology of disease through immunotherapeutic mechanisms for sustained and durable responses. Founded in 2012, ARMO is backed by investors Kleiner Perkins Caufield & Byers, OrbiMed, DAG Ventures, and NanoDimension.

Contact

Angela Bitting
Bitting Communications LLC
For ARMO BioSciences, Inc.
(925) 202-6211
a.bitting@comcast.net

or

ARMO BioSciences, Inc.
contact@armobio.com
(650) 779-5075
www.armobio.com